Continue to Site

Drug Discovery and Development

Neuron23 names chief medical officer

By |

Neuron23The early-stage biotech Neuron23 has appointed Dr. Sam Jackson as its first chief medical officer.

South San Francisco, California–based Neuron23 specializes in developing precision medicines for genetically-defined neurological and immunological diseases.

Jackson is a board-certified emergency physician with fellowship training in medical toxicology.

“I am thrilled to welcome Dr. Jackson to our growing Neuron23 leadership team,” said Nancy Stagliano, CEO of Neuron23, in a statement.

Sam Jackson

Dr. Sam Jackson

Neuron23 is working to advance NEU-723, a brain-penetrant LRRK2 inhibitor for Parkinson’s disease, into clinical trials.

Previously, Jackson worked as the senior vice president and chief medical officer of Alector (Nasdaq:ALEC), a biopharma developing therapies for neurodegeneration diseases.

Neuron23 was founded in 2018 to focus on neurodegenerative diseases, neuroinflammatory diseases and systemic autoimmune and inflammatory diseases.

In late March 2022, the company closed a $100 Million Series C financing round and selected NEU-723 as a clinical candidate for Parkinson’s.

 

 

Filed Under: Neurological Disease
Tagged With: , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development